

## Review Article

# Systemic Lupus Erythematosus: Pathogenesis at the Functional Limit of Redox Homeostasis

Jay Pravda 

Therashock LLC, 4371 Northlake Blvd #247, Palm Beach Gardens Fl 33410, USA

Correspondence should be addressed to Jay Pravda; jaypravda1@gmail.com

Received 3 May 2019; Revised 15 August 2019; Accepted 9 September 2019; Published 26 November 2019

Academic Editor: Hamid Reza Rezvani

Copyright © 2019 Jay Pravda. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Systemic lupus erythematosus (SLE) is a disease characterized by the production of autoreactive antibodies and cytokines, which are thought to have a major role in disease activity and progression. Immune system exposure to excessive amounts of autoantigens that are not efficiently removed is reported to play a significant role in the generation of autoantibodies and the pathogenesis of SLE. While several mechanisms of cell death-based autoantigenic exposure and compromised autoantigen removal have been described in relation to disease onset, a significant association with the development of SLE can be attributed to increased apoptosis and impaired phagocytosis of apoptotic cells. Both apoptosis and impaired phagocytosis can be caused by hydrogen peroxide whose cellular production is enhanced by exposure to endogenous hormones or environmental chemicals, which have been implicated in the pathogenesis of SLE. Hydrogen peroxide can cause lymphocyte apoptosis and glutathione depletion, both of which are associated with the severity of SLE. The cellular accumulation of hydrogen peroxide is facilitated by the myriad of stimuli causing increased cellular bioenergetic activity that enhances metabolic production of this toxic oxidizing agent such as emotional stress and infection, which are recognized SLE exacerbating factors. When combined with impaired cellular hydrogen peroxide removal caused by xenobiotics and genetically compromised hydrogen peroxide elimination due to enzymatic polymorphic variation, a mechanism for cellular accumulation of hydrogen peroxide emerges, leading to hydrogen peroxide-induced apoptosis and impaired phagocytosis, enhanced autoantigen exposure, formation of autoantibodies, and development of SLE.

## 1. Introduction

Systemic lupus erythematosus (SLE) is an immune-mediated disease whose originating pathogenesis results in autoantigen exposure giving rise to numerous autoreactive antibodies of varying antigenic specificities that along with a myriad of cytokines are thought to be effectors of disease activity. Genetic susceptibility and environmental factors play important roles in disease development [1, 2]. Studies have shown that repeated immunization in mice not prone to autoimmune disease reproducibly led to the development of systemic autoimmunity [3, 4]. A similar autoimmune response is seen in mice not prone to autoimmunity when macrophages are chemically depleted [5]. Macrophages are required to remove apoptotic cells and prevent autoantigen exposure from apoptotic cells undergoing secondary necrosis. This suggests that increased

autoantigenic exposure via increased autoantigenic load or decreased removal is an early event in the pathogenesis of SLE. Macrophages are reported to undergo increased apoptosis when presented with excess apoptotic loads, which increases exposure and decreases removal of autoantigens [6]. When viewed in light of an SLE monozygotic concordance rate as low as 24%, we can reasonably speculate that an important role for environmental factors in the pathogenesis of SLE is to facilitate autoantigenic exposure to the adaptive immune system [7]. This suggests that increased autoantigenic exposure and decreased autoantigen removal are early concomitants in the pathogenesis of SLE.

Several different mechanisms of cell death have been described with the potential of exposing intracellular autoantigens to the immune system [8–10]. However, apoptosis is believed to play a significant role in pathological autoantigen presentation because of the sheer volume of cellular mass

normally undergoing apoptosis amounting to 150 billion cells a day or over 10% of total cellular body mass per month [11]. Cells undergoing apoptosis are normally phagocytosed by professional phagocytes such as macrophages; however, studies in individuals with SLE report increased numbers of cells undergoing apoptosis accompanied by impaired phagocytosis [8, 12]. A contemporaneous occurrence of enhanced apoptosis and impaired phagocytosis is considered a key process in the pathogenesis of SLE and can lead to the cumulative exposure of autoantigens resulting in autoantibody production and autoimmunity [8, 13]. This suggests a systemic agent capable of enhancing apoptosis while simultaneously compromising phagocytosis.

Enhanced apoptosis has been associated with depleted glutathione in lymphocytes of patients with SLE [14]. Because glutathione is the major reducing agent responsible for the neutralization of cellular hydrogen peroxide ( $H_2O_2$ ), a reduction in cellular glutathione will result in elevated cellular  $H_2O_2$ . Hydrogen peroxide is a potent apoptosis-inducing agent [15–19], and studies have demonstrated apoptosis in human lymphocytes exposed to  $H_2O_2$  concentrations as low as  $0.7 \mu M$ , making lymphocytes one of the most sensitive cells in the body to the apoptotic effect of  $H_2O_2$  [20]. Hydrogen peroxide is also capable of causing impaired macrophage phagocytosis [21]. When both effects of  $H_2O_2$  are combined, a role for  $H_2O_2$  in the pathogenesis of SLE is a reasonable consideration. Consistent with this interpretation are studies showing significantly increased serum  $H_2O_2$  of up to  $220 \mu M$  associated with anti-dsDNA antibodies and tissue damage in a murine model of SLE [22]. Contemporaneous lymphocyte apoptosis and impaired macrophage phagocytosis are reported to show a significant correlation with disease activity in individuals with SLE lending further support for a role for  $H_2O_2$  in the pathogenesis of SLE [23]. Apoptosis and impaired phagocytosis occur once lymphocytes and macrophages have surpassed their functional limit of redox homeostasis allowing the intracellular accumulation of toxic levels of  $H_2O_2$ . Redox homeostasis refers to a stable equilibrium that arises between the generation of toxic reactive oxygen species and their continuous removal by the cell [24]. Impaired redox homeostasis leads to cellular buildup of  $H_2O_2$ . The majority of the biological effects of reactive oxidant species are mediated by  $H_2O_2$  [25].

Taken together, this suggests that  $H_2O_2$  has a causal role in the impaired macrophage phagocytosis in addition to macrophage and lymphocyte apoptosis that leads to the development of SLE. When integrating important disease-modulating elements contained within the exposome and genotype, we can postulate that exposure to environmental oxidative stressors (which generate  $H_2O_2$ ) in a setting of genetically reduced ability to remove  $H_2O_2$  contributes to impaired redox homeostasis and elevated cellular  $H_2O_2$  facilitating apoptosis, enhanced autoantigenic exposure, autosensitization, and development of SLE (Figure 1). The remainder of this paper will expand upon the causal role of hydrogen peroxide-mediated apoptosis and impaired phagocytosis in response to endogenous

and exogenous oxidative stress exposure in the pathogenesis of SLE.

## 2. A Causal Role for $H_2O_2$ -Induced Apoptosis in the Pathogenesis of SLE

Hydrogen peroxide has a central role in controlling apoptosis.  $H_2O_2$  can initiate apoptosis via caspase-dependent (ASK-1) and caspase-independent pathways. Caspase-independent apoptosis involves  $H_2O_2$ -induced release of mitochondrial AIF (apoptosis-inducing factor), which directly initiates DNA condensation and apoptosis after translocation to the nucleus. Protein components of the *mitochondrial* permeability transition pore (MPTP) such as the voltage-dependent anion channel in the outer mitochondrial membrane, adenine nucleotide translocator in the inner mitochondrial membrane, and cyclophilin-D in the mitochondrial matrix are targets of  $H_2O_2$  and undergo oxidative modifications that will stimulate MPTP opening and apoptosis [18, 34].  $H_2O_2$  is thus a potent multipathway initiator of apoptosis that can trigger mass lymphocyte apoptosis during clonal expansion if cell levels of  $H_2O_2$  are allowed to increase.

$H_2O_2$  is continuously generated as a byproduct of cellular metabolic activity including protein synthesis (disulfide bond formation), DNA recycling (xanthine oxidase), fatty acid oxidation (peroxisomal metabolism), and dozens of human enzymes [35–39]. The principal source of cellular hydrogen peroxide is mitochondrial electron transport chain autooxidation during oxidative phosphorylation [38]. Hydrogen peroxide, a potent oxidizing agent, must be neutralized within the cell to prevent toxic accumulation. This is largely accomplished by glutathione-based reductive enzyme systems [40–43]. However, if the production of  $H_2O_2$  during a hypermetabolic response overwhelms the cell's reductive capacity, then excess  $H_2O_2$  can accumulate within the cell and trigger apoptosis.

In this regard, lymphocyte clonal expansion has been described as a “metabolic bomb” that explodes in a proliferative chain reaction during which glycolysis, the Krebs cycle, and oxidative phosphorylation (electron transport chain) are upregulated to provide the necessary energy in the form of ATP in order to fuel increased metabolic demands that occur during a response to infection [44]. Accompanying this increased metabolic activity is greatly enhanced generation of mitochondrial hydrogen peroxide ( $H_2O_2$ ) as a byproduct of electron transport chain activity and enzymatic reactions involved in the Krebs cycle (alpha-ketoglutarate dehydrogenase) [45, 46]. If  $H_2O_2$  generated during cellular activation and highly metabolic states overwhelm the cell's reductive (antioxidant) capacity, the  $H_2O_2$  buildup can trigger apoptosis.

Physiological lymphocyte apoptosis occurs during immune catabasis (downregulation after an immune response) after days of clonal expansion, but the appearance of lymphocytopenia during active SLE suggests that this mechanism has been improperly triggered during the initial phases of lymphocyte clonal expansion [47–51]. This is consistent with  $H_2O_2$ -induced lymphocyte apoptosis and




FIGURE 1: SLE pathogenesis: genetic predisposition stemming from decreased reductive capacity (low glutathione) and diminished reductive reserve due to reduced enzymatic activity in glutathione synthesis combined with environmental factors acting as hydrogen peroxide-generating oxidant stressors results in glutathione (GSH) depletion and increases lymphocyte and macrophage intracellular hydrogen peroxide (a potent apoptotic agent) leading to lymphocyte and macrophage apoptosis. Rising hydrogen peroxide ( $H_2O_2$ ) will impair macrophage phagocytosis before causing apoptosis. Enhanced apoptosis and impaired phagocytosis expose autoantigens to the adaptive immune system that responds with autoantibodies and cytokines resulting in autoimmunity and SLE. Elevated homocysteine (reported in SLE) inhibits glutathione peroxidase (GPX) needed for  $H_2O_2$  neutralization [26, 27]. Decreased activity of enzymes needed for  $H_2O_2$  elimination such as catalase (CAT), glutathione peroxidase (GPx), and glutathione cysteine ligase (GCL) has also been reported in SLE [14, 28–30]. A genetically determined variation of up to one order of magnitude in plasma GSH concentration places a subset of individuals at the lower range of normal and at greater risk of  $H_2O_2$ -induced oxidative stress [31–33]. Lymphocyte apoptosis contributes to lymphopenia observed in SLE.

supported by studies showing depleted glutathione and lymphocyte apoptosis during active SLE [52–54]. In addition to enhanced  $H_2O_2$  production, a preexisting impaired cellular reductive capacity compromising the cell's ability to neutralize  $H_2O_2$  is suggested by studies reporting significantly increased sensitivity of SLE lymphocytes to the cytotoxic effects of  $H_2O_2$  compared to control lymphocytes [55]. This is consistent with a preexisting impairment in reductive capacity/reserve and a role for  $H_2O_2$  in the pathogenesis of SLE. Thus, a hypermetabolic lymphocyte response can generate excess  $H_2O_2$  leading to apoptosis.

Estrogen and emotional stress are two examples of  $H_2O_2$ -generating hypermetabolic triggers that are associated with SLE as explained below.

**2.1. Estrogen.** Estrogen-induced apoptosis has previously been reported and is dependent upon the estrogen receptor [56]. Lymphocytes express estrogen receptors that initiate signal transduction and enhance lymphocyte metabolism, which generates increased  $H_2O_2$  [57, 58]. Additional studies have reported significantly decreased ability to metabolize hydrogen peroxide with a parallel decrease in cellular glutathione when human cell lines were treated with estrogen [59]. A factor contributing to the decrease in glutathione and inability to metabolize  $H_2O_2$  during estrogen treatment may be due to the requirement for NADPH in the cytochrome P450 oxidase-mediated catabolism of estrogen [60]. In addition to being consumed in estrogen catabolism,

NADPH is also required as a source of reducing equivalents for cellular regeneration of glutathione by glutathione disulfide reductase (EC 1.8.1.7), an important source of cellular glutathione [61]. Thus, estrogen catabolism competes for this critical source of reducing equivalents needed for glutathione regeneration in the cell resulting in sequestration of NADPH away from reduced glutathione regeneration. This can lead to decreased cellular glutathione and the inability to metabolize  $H_2O_2$ , as observed. This suggests that estrogen's initiating effect in SLE pathogenesis and exacerbating effect in disease progression stem from enhanced metabolic generation of  $H_2O_2$  in a setting of genetic and/or induced impaired reductive capacity that can lead to higher levels of lymphocyte  $H_2O_2$  with subsequent  $H_2O_2$ -induced apoptosis and autoantibody formation. This effect would be more pronounced in females as they have higher circulating levels of estrogenic hormones than males.

Hydrogen peroxide-induced apoptosis and release of autoantigens are consistent with studies showing that estrogen enhances severity and flares of SLE in both human and animal models [57, 58]. Finally, since oxidative stress can be additive, the higher levels of estrogenic hormones in females can also lead to a priming effect, increasing sensitivity to apoptosis from exposure to natural and synthetic compounds with estrogenic activity in the food, soil, air, and water that enter the body via the oral, inhaled, and dermal routes resulting in impaired redox homeostasis [62, 63].

“Full-blown” SLE developing in previously healthy women after ovulation induction therapy has been reported [64]. Ovulation induction therapy significantly raises estrogen levels suggesting a physiological effect of estrogen in the pathogenesis of SLE. This is consistent with estrogen-induced hypermetabolic generation of  $H_2O_2$  and subsequent  $H_2O_2$ -induced mass lymphocyte apoptosis.

**2.2. Emotional Stress.** Emotional stress is a recognized factor associated with SLE onset and exacerbation [65, 66]. Stress increases adrenergic hormone secretion from adrenal glands and the sympathetic nervous system [67, 68]. All lymphocytes express adrenergic receptors that are activated by adrenergic hormones [69, 70]. Adrenergic receptor activation dramatically alters lymphocyte proliferation, differentiation, protein synthesis, and cytokine/antibody production and secretion [71, 72]. These large functional changes are reflected in mitochondrial metabolism, and studies have shown that norepinephrine-stimulated lymphocytes generate increased mitochondrial superoxide [73]. Superoxide undergoes immediate enzymatic conversion to  $H_2O_2$  at the site of production within mitochondria by the enzyme superoxide dismutase (EC 1.15.1.1) [74]. Lymphocyte activation also causes mitochondrial hyperpolarization leading to a more reduced electron transport chain [75]. This increases electron leakage from the ETC leading to enhanced  $H_2O_2$  production.

Thus, acute stressful stimuli can flood the body with adrenergic hormones and in a setting of inadequate reductive capacity/reserve (i.e., decreased glutathione) can lead to accumulation of excess  $H_2O_2$  within lymphocytes resulting in mass apoptosis and subsequent intracellular antigen exposure. By this fashion, continued stress-induced autoantigen exposure may contribute to the onset or exacerbation of SLE. Consistent with this interpretation are studies showing that psychological stress increases human lymphocyte apoptosis [76].

**2.3. Mercury.** Mercury is an example of a highly toxic oxidative stressor that can accumulate in the body. Mercury is a ubiquitous contaminant in the environment, and studies have documented significantly elevated blood levels of mercury in patients with SLE that independently correlated with disease activity [77, 78]. Mercury is a reductive depleting agent that irreversibly binds reduced thiol groups present in glutathione and other proteins [79, 80]. This inactivates glutathione, which can no longer fulfil its role in the removal of hydrogen peroxide. Mercury also inactivates glutathione peroxidase, the principal enzyme involved in  $H_2O_2$  elimination [81]. The end result facilitates a rise in cellular  $H_2O_2$  which can lead to apoptosis. This suggests that chronic mercury exposure is an oxidative stressor that contributes to apoptosis and autoantigen exposure with subsequent autoantibody formation, which may increase the risk of SLE development in the future.

Consistent with this interpretation are studies showing subclinical autoimmunity (anti-DNA antibodies) in reproductive-age human females with low levels of blood mercury generally considered safe [82]. The observed low-

level mercury exposure associated with subclinical autoimmunity suggests a contribution from other oxidative stressors. This is supported by murine models of SLE that were worsened by nontoxic amounts of mercury exposure [83]. Thus, mercury exposure can deplete glutathione causing  $H_2O_2$  levels to increase, which increases the risk of apoptosis, autoantigenic exposure, and development and/or worsening of SLE.

### 3. Endogenous Oxidative Stressors

**3.1. Homocysteine.** Endogenous metabolites can also contribute to oxidative stress-induced lymphocyte apoptosis and autoantigenic exposure. Homocysteine is a nonproteogenic amino acid breakdown product of protein metabolism whose serum concentration is frequently elevated in children and adults with SLE [84, 85]. Homocysteine has been reported to inhibit GPx activity by 10-fold, and inhibition of GPx was shown to occur at physiologic ( $9 \mu\text{mol/L}$ ) concentrations of free homocysteine [24, 25]. Homocysteine also downregulates cellular glutathione peroxidase by decreasing translation of this enzyme [86]. As mentioned above, glutathione peroxidase is the principal antioxidant enzyme utilizing glutathione as reductive cofactor for the reduction (neutralization) of cellular hydrogen peroxide. A reduction in the activity of this critical enzyme can increase cellular hydrogen peroxide, which can contribute to lymphocyte oxidative stress, apoptosis, autoantigen exposure, and worsening of SLE. Consistent with this interpretation are studies showing that increased homocysteine serum levels correlate with disease severity in patients with lupus erythematosus [87].

**3.2. Mitochondrial Heteroplasmy and SLE.** Mitochondrial heteroplasmy (MH) is a form of acquired endogenous oxidative stress that is self-amplifying, internally reinforcing, and mutagenic. MH occurs when  $H_2O_2$  reacts with mitochondrial DNA (mtDNA) inflicting oxidative damage. This introduces mtDNA mutations, which increase lymphocyte  $H_2O_2$  in a self-amplifying vicious cycle that increased cellular steady-state  $H_2O_2$  levels that facilitate lymphocyte apoptosis and autoantigenic exposure. The self-perpetuating nature of MH can result in significant, continuous, and mounting endogenous lymphocyte  $H_2O_2$ . In support of this interpretation and a role for  $H_2O_2$  in the pathogenesis of SLE, studies have shown significant mitochondrial heteroplasmy and  $H_2O_2$  production in lymphocytes of individuals with SLE, and mitochondrial heteroplasmy is reported to be related to the development and progression of SLE [88–90].

Mitochondrial DNA is highly vulnerable to  $H_2O_2$ -induced oxidative damage due to the proximity of mtDNA to the electron transport chain (ETC), both of which reside on the matrix side of the inner mitochondrial membrane. Mutated mtDNA will result in base mutations and nucleotide mispairing that, upon transcription, lead to the incorporation of mutated protein subunits into the ETC [91–94]. Mutated ETC components will interfere with electron transport leading to further electron leakage and increased  $H_2O_2$  production [95–98]. This establishes a self-amplifying vicious cycle in which  $H_2O_2$ -induced mtDNA damage results

in greater amounts of ETC-generated  $H_2O_2$  which, in turn, further damage mtDNA leading to increasingly greater degrees of mitochondrial heteroplasmy and ETC dysfunction with higher steady-state levels of intracellular  $H_2O_2$  [93–96, 99, 100]. Once mtDNA oxidative damage (heteroplasmy) has occurred, the entire process is self-perpetuating and self-amplifying. The end result is exhausted glutathione, mitochondrial hyperpolarization, and depleted ATP due to rising mitochondrial generation of  $H_2O_2$ . Elevated lymphocyte  $H_2O_2$  promotes apoptosis and autoantigenic exposure.

Taken together, this suggests a natural history of disease in which cumulative and additive oxidative stress from the interaction of genetic predisposition (decreased reductive capacity/reserve), endogenous sources (hormones, metabolites, and mitochondrial heteroplasmy), and exogenous chemicals (xenobiotics) combines to persistently increase intracellular  $H_2O_2$  resulting in enhanced lymphocyte apoptosis. Elevated lymphocyte  $H_2O_2$  can cause spontaneous apoptosis or lower the threshold for oxidative stress to trigger apoptosis. This can result in exposure of intracellular autoantigenic material to the adaptive immune system and subsequent development of autoimmunity if apoptotic cells are not efficiently removed by phagocytosis.

However, as described in the next section, impaired phagocytosis is present in SLE suggesting enhanced apoptosis and impaired phagocytosis are core contributory components in the pathogenesis of SLE.

#### 4. Immune Shielding: Phagocytosis of Apoptotic Cells

Phagocytosis of apoptotic cells “shields” the immune system from autoantigens. However,  $H_2O_2$  can cause impaired phagocytosis in addition to apoptosis of phagocytes (i.e., macrophages) that are needed to remove apoptotic cells. This contributes to autoantigenic exposure as discussed below.

Up to 150 billion cells die every day in the human body [11]. This represents over 10% of total cellular body mass each month. This physiological cell death, known as apoptosis, is programmed to occur as old cells are replaced with new ones. If apoptosis of this large dying cell mass is allowed to proceed unchecked, it would continuously expose intracellular autoantigens to the adaptive immune system as dying apoptotic cells undergo secondary necrosis and intracellular autoantigenic contents are released into the extracellular environment or bloodstream where they would elicit an immune response [101, 102]. This does not normally happen because the adaptive immune system is mostly shielded from exposure to autoantigens by phagocytes (i.e., macrophages) that can identify cells undergoing apoptosis and target them for phagocytosis, which safely degrades autoantigens, preventing immune activation [10, 13, 103, 104].

However, phagocytosis is impaired in SLE [105]. Impaired macrophage phagocytosis increases autoantigenic load and is additive to enhanced lymphocyte apoptosis because both anomalies increase autoantigenic exposure to the adaptive immune system resulting in autoimmunity and hypercytokinemia. The contemporaneous presence of

enhanced apoptosis and impaired phagocytosis suggests a common mechanism leading to both abnormalities.

Engulfment of apoptotic cells by professional motile phagocytes (i.e., macrophages, neutrophils) requires migration to the apoptotic body and subsequent phagocytosis, both of which are energy-intensive processes [11, 106, 107]. This generates large amounts of  $H_2O_2$  from both the NADPH oxidase complex and electron transport chain autooxidation [108]. Additionally, macrophages make extensive use of the amino acid glutamine as an anaplerotic precursor to replenish Krebs cycle intermediary metabolites [107, 109]. Glutamine is also required for glutathione biosynthesis in order to effectively metabolize cellular hydrogen peroxide. Thus, under conditions of sustained phagocytic activity (during periods of enhanced apoptosis, i.e., SLE) when demand for glutathione to neutralize cellular  $H_2O_2$  is high, the availability of glutathione may be limited due to increased anaplerotic metabolism of glutamine within phagocytes. This can result in glutathione depletion and elevated phagocyte  $H_2O_2$  levels. This view is supported by studies showing depleted neutrophil glutathione levels in patients with SLE suggesting elevated cellular  $H_2O_2$  [110]. Large energetic and anaplerotic requirements make the process of phagocytosis a significant oxidative stressor to professional motile phagocytes such as macrophages and neutrophils, which increased cellular  $H_2O_2$ .

The finding in SLE patients that glutathione is depleted in other nonphagocytic cell lines such as erythrocytes and lymphocytes in addition to serum and plasma suggests depletion of blood reductive capacity with subsequent elevation in serum  $H_2O_2$  levels [111]. Apoptosis occurring throughout the body in other tissues such as the bone marrow, endothelium, skin, kidney, neutrophils, lymphocytes, and macrophages is consistent with systemically elevated serum  $H_2O_2$ , which is a potent cell membrane-permeable oxidizing agent capable of inducing intrinsic pathway apoptosis in most any tissue or cell line [53, 112–119]. This is supported by multiple abnormalities in bone marrow stem cells such as increased intrinsic pathway apoptosis, dysfunctional mitochondrial signaling pathways, and increased mitochondrial superoxide production consistent with  $H_2O_2$ -mediated oxidative damage and  $H_2O_2$ -induced mitochondrial hyperpolarization [120]. Multiple aberrations in activation status and secretory functions of circulating and tissue-infiltrating monocytes and macrophages are consistent with indiscriminate  $H_2O_2$ -induced oxidative damage [121].

In other words, excess  $H_2O_2$  originating from intra- or extracellular sources can diffuse throughout cells and their organelles causing indiscriminate oxidative damage to multiple targets resulting in a myriad of functional abnormalities. Excess cellular  $H_2O_2$  results in impaired phagocytosis and apoptosis of phagocytes (macrophages, neutrophils) in addition to apoptosis of virtually any cell line contributing to autoantigenic exposure and development of or worsening of SLE [16].

#### 5. Discussion

The list of abnormalities associated with SLE is voluminous and reflective of the various cytokines and numerous

autoantibodies that can affect any part of the body. With an originating pathogenesis that is buried deep in the past at the time of diagnosis, the pathophysiology develops unhindered and unrecognized until clinical disease becomes evident. Extensive research into the pathogenesis of SLE has identified over 100 autoantibodies of different antigenic specificity appearing up to a decade prior to disease onset [122, 123].

The recognition that individuals with SLE have increased apoptosis and impaired phagocytosis suggests a pathogenesis mediated principally by increased adaptive immune system exposure to an ever-increasing autoantigenic load. The dual presence of enhanced apoptosis and impaired phagocytosis points to a common underlying mechanism. When paired with the finding of depleted glutathione in individuals with SLE, this suggests the involvement of  $H_2O_2$ . Hydrogen peroxide is a potent oxidizing and apoptosis-inducing agent that can also impair phagocytosis. Glutathione is needed to neutralize  $H_2O_2$ , and in the absence of glutathione,  $H_2O_2$  levels will increase.

Studies have shown that SLE serum can induce apoptosis in healthy lymphocytes, and this is mediated via the intrinsic (mitochondrial) pathway independent of death receptors and is unaffected by heat inactivation or IgG absorption [124, 125]. Serum from patients with active SLE accelerated apoptosis of macrophages from healthy subjects, and SLE serum is also reported to impair the phagocytic activity of healthy control macrophages, which was restored upon exposure to normal serum [126]. These observations are consistent with the known effects of  $H_2O_2$ , which is cell membrane permeable and capable of inducing the intrinsic (mitochondrial) apoptosis pathway [17, 19, 127].

Normalization of macrophage phagocytosis by healthy serum can be attributed to normal serum's ability to act as a reductive sink facilitating diffusion of excess intracellular  $H_2O_2$  to the extracellular environment and restoration of normal macrophage redox potential by internalizing reducing equivalents (i.e., cysteine) contained in normal serum in order to replenish depleted cellular reductive capacity (i.e., glutathione) [128].

Taken together, the data suggest that a significant contributing mechanism involved in disease initiation is dependent upon  $H_2O_2$ -induced glutathione depletion followed by  $H_2O_2$ -mediated apoptosis and impaired phagocytosis resulting in autoantigenic exposure to the adaptive immune system with subsequent autoantibody and cytokine production culminating in SLE.

Oxidative stress, the ability to increase cellular  $H_2O_2$ , can be caused by multiple environmental chemical xenobiotics and hormones, either by directly depleting glutathione or by signal transduction-induced cellular activation [129]. Thus, continuous endogenous  $H_2O_2$ -mediated oxidative stress lowers the threshold for disease exacerbation by exogenous oxidative stressors leading to increased lymphocyte apoptosis whose cellular debris is inefficiently removed. Once initiated, a network of pathological positive biofeedback mechanisms leads to a heightened immune reactive state involving multiple immune effector cells including T and B cells (Figure 2). The end result is an alphabet of autoanti-




FIGURE 2: Pathogenesis of SLE: network diagram. Network diagram of SLE showing self-reinforcing positive biofeedback circuits. External (xenobiotics) (n-1) and internal (n-5) oxidative stressors (estrogen, stress hormones, and mitochondrial heteroplasmy) generate lymphocyte and macrophage hydrogen peroxide ( $H_2O_2$ ) (e1, e2, e5, and e6) that increases apoptosis (n-2) and impairs phagocytosis (n-4). The increased autoantigenic exposure leads to cytokine and autoantibody production by the adaptive immune system (e3, e4), which results in autoimmunity and SLE (n-3). Internal oxidative stress is continuous and fuels apoptosis and impaired phagocytosis. The process of phagocytosis itself is an oxidative stressor that can contribute to impaired phagocytosis (e8). Macrophages also undergo  $H_2O_2$ -induced apoptosis that increases autoantigenic load and reduces phagocytosis (e9). Autoantibodies and cytokines generate  $H_2O_2$  due to Fc peroxide activity and signal transduction, respectively (e7), resulting in a self-reinforcing pathological feedback circuit making serological remission a rare occurrence [22, 57, 58, 130–132]. E=edge, n=node.

bodies within a serum cytokine soup replete with  $H_2O_2$  that can cause dysfunction of almost any organ in the body making prolonged remission a rarity [130–132].

Lymphocytes are highly sensitive to  $H_2O_2$ -induced apoptosis. This sensitivity to apoptosis can have a physiological role in order to appropriately downregulate an immune response after infection but can also be co-opted by environmental oxidative stressors that can inappropriately induce apoptosis by increasing cellular  $H_2O_2$ . Xenobiotic chemicals can remain in the body for extended periods of time causing a cumulative endogenous oxidative stress that contributes to a lower threshold for future oxidative stress-induced disease exacerbations. This suggests that, in most cases, SLE does not start out as a primary immune-mediated disease but evolves into one after reductive capacity is depleted and redox homeostasis becomes impaired resulting in increased apoptosis, impaired phagocytosis, and autoimmunity. This distinction has practical implications for altering the natural history of disease because it suggests that the long latent period between the appearance of autoantibodies and disease onset is the time during which redox homeostasis is becoming progressively more disrupted and when intervention to

correct impaired redox homeostasis may prevent development of disease.

## 6. Conclusion

Decades of research attempting to “reverse engineer” systemic lupus erythematosus (SLE) have led to the understanding that autoantigenic exposure triggers immune activation causing symptoms, signs, and organ pathology we recognize as SLE. We are now at the level of identifying an initiating cell type and mechanism whereby this can occur and integrate these elements with compatible genetic predisposition and environmental factors that enhance autoantigenic exposure leading to disease.

The data suggest that  $H_2O_2$ -induced apoptosis of lymphocytes and macrophages plays a prominent causal role in the pathogenesis of SLE. The high sensitivity of lymphocytes to  $H_2O_2$ -induced apoptosis at submicromolar exposure levels suggests that this mechanism is a major early initiating event exposing the adaptive immune system to cellular autoantigens.  $H_2O_2$  also impairs macrophage phagocytosis of apoptotic cells and additionally triggers macrophage apoptosis. The end effect is enhanced and prolonged autoantigenic exposure as a result of increased apoptosis and decreased phagocytosis of apoptotic cells.

A preexisting genetic disposition which compromises the ability to neutralize  $H_2O_2$  in addition to environmental factors that increase lymphocyte  $H_2O_2$  (oxidative stress) or decrease cellular reductive capacity contributes to apoptosis and autoantigenic exposure. This suggests that lymphocyte screening for  $H_2O_2$  and glutathione levels may predict risk of developing SLE. It also suggests that preventive measures aimed at avoidance of environmental oxidative stressors (all of which increase  $H_2O_2$ ) and augmenting individual reductive capacity (i.e., glutathione) can treat and prevent disease [133, 134]. This implies that fortifying the food supply with reducing equivalents may be able to offer protection on a population level against oxidative stress-induced apoptosis and prevent the development of SLE and other diseases mediated by oxidative stress.

## Conflicts of Interest

The author declares that he has no conflicts of interest.

## References

- [1] L. Lisnevskaja, G. Murphy, and D. Isenberg, “Systemic lupus erythematosus,” *Lancet*, vol. 384, no. 9957, pp. 1878–1888, 2014.
- [2] A. Kaul, C. Gordon, M. K. Crow et al., “Systemic lupus erythematosus,” *Nature Reviews Disease Primers*, vol. 2, no. 1, 2016.
- [3] S. Shiozawa, “The cause of systemic lupus erythematosus: implication of ‘self-organized criticality theory of autoimmunity’ on the pathogenesis of systemic lupus erythematosus,” *International Journal of Clinical Rheumatology*, vol. 5, no. 6, pp. 619–626, 2010.
- [4] K. Tsumiyama, Y. Miyazaki, and S. Shiozawa, “Self-organized criticality theory of autoimmunity,” *PLoS One*, vol. 4, no. 12, article e8382, 2009.
- [5] M. F. Denny, P. Chandaroy, P. D. Killen et al., “Accelerated macrophage apoptosis induces autoantibody formation and organ damage in systemic lupus erythematosus,” *The Journal of Immunology*, vol. 176, no. 4, pp. 2095–2104, 2006.
- [6] N. Jiang, C. F. Reich III, and D. S. Pisetsky, “Role of macrophages in the generation of circulating blood nucleosomes from dead and dying cells,” *Blood*, vol. 102, no. 6, pp. 2243–2250, 2003.
- [7] D. Deafen, A. Escalante, L. Weinrib et al., “A revised estimate of twin concordance in systemic lupus erythematosus,” *Arthritis & Rheumatism*, vol. 35, no. 3, pp. 311–318, 1992.
- [8] P. Mistry and M. J. Kaplan, “Cell death in the pathogenesis of systemic lupus erythematosus and lupus nephritis,” *Clinical Immunology*, vol. 185, pp. 59–73, 2017.
- [9] A. Mahajan, M. Herrmann, and L. E. Muñoz, “Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE,” *Frontiers in Immunology*, vol. 7, 2016.
- [10] M. J. Podolska, M. H. Biermann, C. Maueröder, J. Hahn, and M. Herrmann, “Inflammatory etiopathogenesis of systemic lupus erythematosus: an update,” *Journal of Inflammation Research*, vol. 8, 2015.
- [11] M. R. Elliott and K. S. Ravichandran, “The dynamics of apoptotic cell clearance,” *Developmental Cell*, vol. 38, no. 2, pp. 147–160, 2016.
- [12] M. H. Biermann, S. Veissi, C. Maueröder et al., “The role of dead cell clearance in the etiology and pathogenesis of systemic lupus erythematosus: dendritic cells as potential targets,” *Expert Review of Clinical Immunology*, vol. 10, no. 9, pp. 1151–1164, 2014.
- [13] L. E. Munoz, C. van Bavel, S. Franz, J. Berden, M. Herrmann, and J. van der Vlag, “Apoptosis in the pathogenesis of systemic lupus erythematosus,” *Lupus*, vol. 17, no. 5, pp. 371–375, 2008.
- [14] D. Shah, S. Sah, A. Wanchu, M. X. Wu, and A. Bhatnagar, “Altered redox state and apoptosis in the pathogenesis of systemic lupus erythematosus,” *Immunobiology*, vol. 218, no. 4, pp. 620–627, 2013.
- [15] H. J. Lin, X. Wang, K. M. Shaffer, C. Y. Sasaki, and W. Ma, “Characterization of  $H_2O_2$ -induced acute apoptosis in cultured neural stem/progenitor cells,” *FEBS Letters*, vol. 570, no. 1–3, pp. 102–106, 2004.
- [16] J. Xiang, C. Wan, R. Guo, and D. Guo, “Is hydrogen peroxide a suitable apoptosis inducer for all cell types?,” *BioMed Research International*, vol. 2016, Article ID 7343965, 2016.
- [17] M. Singh, H. Sharma, and N. Singh, “Hydrogen peroxide induces apoptosis in HeLa cells through mitochondrial pathway,” *Mitochondrion*, vol. 7, no. 6, pp. 367–373, 2007.
- [18] M. Redza-Dutordoir and D. A. Averill-Bates, “Activation of apoptosis signalling pathways by reactive oxygen species,” *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research*, vol. 1863, no. 12, pp. 2977–2992, 2016.
- [19] X. Luo, B. Chen, R. Zheng, P. Lin, J. Li, and H. Chen, “Hydrogen peroxide induces apoptosis through the mitochondrial pathway in rat Schwann cells,” *Neuroscience Letters*, vol. 485, no. 1, pp. 60–64, 2010.
- [20] F. Antunes and E. Cadenas, “Cellular titration of apoptosis with steady state concentrations of  $H_2O_2$ : submicromolar levels of  $H_2O_2$  induce apoptosis through Fenton chemistry

- independent of the cellular thiol state," *Free Radical Biology & Medicine*, vol. 30, no. 9, pp. 1008–1018, 2001.
- [21] R. S. Oosting, L. van Bree, J. F. van Iwaarden, L. M. van Golde, and J. Verhoef, "Impairment of phagocytic functions of alveolar macrophages by hydrogen peroxide," *American Journal of Physiology-Lung Cellular and Molecular Physiology*, vol. 259, no. 2, pp. L87–L94, 1990.
- [22] Y. Wang, B. Qiao, Y. Wang, X. Han, Y. Chu, and S. Xiong, "Autoantibodies closely relate to the elevation level of in vivo hydrogen peroxide and tissue damage in systemic lupus erythematosus," *DNA and Cell Biology*, vol. 25, no. 10, pp. 563–570, 2006.
- [23] O. Jin, L. Y. Sun, K. X. Zhou et al., "Lymphocyte apoptosis and macrophage function: correlation with disease activity in systemic lupus erythematosus," *Clinical Rheumatology*, vol. 24, no. 2, pp. 107–110, 2005.
- [24] F. Ursini, M. Maiorino, and H. J. Forman, "Redox homeostasis: the golden mean of healthy living," *Redox Biology*, vol. 8, pp. 205–215, 2016.
- [25] I. Martínez-Reyes and J. M. Cuezva, "The  $H^+$ -ATP synthase: a gate to ROS-mediated cell death or cell survival," *Biochimica et Biophysica Acta (BBA)-Bioenergetics*, vol. 1837, no. 7, pp. 1099–1112, 2014.
- [26] G. R. Upchurch Jr., G. N. Welch, A. J. Fabian et al., "Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase," *The Journal of Biological Chemistry*, vol. 272, no. 27, pp. 17012–17017, 1997.
- [27] N. Chen, Y. Liu, C. D. Greiner, and J. L. Holtzman, "Physiologic concentrations of homocysteine inhibit the human plasma GSH peroxidase that reduces organic hydroperoxides," *The Journal of Laboratory and Clinical Medicine*, vol. 136, no. 1, pp. 58–65, 2000.
- [28] T. Warchoł, M. Lianeri, M. Wudarski, J. K. Łacki, and P. P. Jagodziński, "Catalase -262C>T polymorphism in systemic lupus erythematosus in Poland," *Rheumatology International*, vol. 28, no. 10, pp. 1035–1039, 2008.
- [29] M. S. Ghaly, M. H. Ghattas, and S. M. Labib, "Association of catalase gene polymorphisms with catalase activity and susceptibility to systemic lupus erythematosus in the Suez Canal area, Egypt," *Lupus*, vol. 21, no. 11, pp. 1244–1249, 2012.
- [30] W. Song, J. Yuan, Z. Zhang, L. Li, and L. Hu, "Altered glutamate cysteine ligase activity in peripheral blood mononuclear cells from patients with systemic lupus erythematosus," *Experimental and Therapeutic Medicine*, vol. 8, no. 1, pp. 195–200, 2014.
- [31] T. J. Van't Erve, B. A. Wagner, K. K. Ryckman, T. J. Raife, and G. R. Buettner, "The concentration of glutathione in human erythrocytes is a heritable trait," *Free Radical Biology & Medicine*, vol. 65, pp. 742–749, 2013.
- [32] F. Michelet, R. Gueguen, P. Leroy, M. Wellman, A. Nicolas, and G. Siest, "Blood and plasma glutathione measured in healthy subjects by HPLC: relation to sex, aging, biological variables, and life habits," *Clinical Chemistry*, vol. 41, no. 10, pp. 1509–1517, 1995.
- [33] H. J. Forman, H. Zhang, and A. Rinna, "Glutathione: overview of its protective roles, measurement, and biosynthesis," *Molecular Aspects of Medicine*, vol. 30, no. 1–2, pp. 1–12, 2009.
- [34] M. L. Circu and T. Y. Aw, "Reactive oxygen species, cellular redox systems, and apoptosis," *Free Radical Biology and Medicine*, vol. 48, no. 6, pp. 749–762, 2010.
- [35] M. Depuydt, J. Messens, and J. F. Collet, "How proteins form disulfide bonds," *Antioxidants & Redox Signaling*, vol. 15, no. 1, pp. 49–66, 2011.
- [36] E. E. Kelley, N. K. Khoo, N. J. Hundley, U. Z. Malik, B. A. Freeman, and M. M. Tarpey, "Hydrogen peroxide is the major oxidant product of xanthine oxidase," *Free Radical Biology & Medicine*, vol. 48, no. 4, pp. 493–498, 2010.
- [37] M. Schrader and H. D. Fahimi, "Mammalian peroxisomes and reactive oxygen species," *Histochemistry and Cell Biology*, vol. 122, no. 4, pp. 383–393, 2004.
- [38] M. P. Murphy, "How mitochondria produce reactive oxygen species," *The Biochemical Journal*, vol. 417, no. 1, pp. 1–13, 2009.
- [39] Y. M. Go, J. D. Chandler, and D. P. Jones, "The cysteine proteome," *Free Radical Biology and Medicine*, vol. 84, pp. 227–245, 2015.
- [40] M. A. Aon, B. A. Stanley, V. Sivakumaran et al., "Glutathione/thioredoxin systems modulate mitochondrial  $H_2O_2$  emission: an experimental-computational study," *The Journal of General Physiology*, vol. 139, no. 6, pp. 479–491, 2012.
- [41] K. Aquilano, S. Baldelli, and M. R. Ciriolo, "Glutathione: new roles in redox signaling for an old antioxidant," *Frontiers in Pharmacology*, vol. 5, 2014.
- [42] P. Venditti, L. Di Stefano, and S. Di Meo, "Mitochondrial metabolism of reactive oxygen species," *Mitochondrion*, vol. 13, no. 2, pp. 71–82, 2013.
- [43] S. C. Lu, "Glutathione synthesis," *Biochimica et Biophysica Acta (BBA) - General Subjects*, vol. 1830, no. 5, pp. 3143–3153, 2013.
- [44] M. D. Buck, D. O'Sullivan, and E. L. Pearce, "T cell metabolism drives immunity," *Journal of Experimental Medicine*, vol. 212, no. 9, pp. 1345–1360, 2015.
- [45] L. Tretter and V. Adam-Vizi, "Generation of reactive oxygen species in the reaction catalyzed by  $\alpha$ -Ketoglutarate Dehydrogenase," *Journal of Neuroscience*, vol. 24, no. 36, pp. 7771–7778, 2004.
- [46] L. Tretter and V. Adam-Vizi, "Alpha-ketoglutarate dehydrogenase: a target and generator of oxidative stress," *Philosophical Transactions of the Royal Society B: Biological Sciences*, vol. 360, no. 1464, pp. 2335–2345, 2005.
- [47] K. Voss, S. E. Larsen, and A. L. Snow, "Metabolic reprogramming and apoptosis sensitivity: defining the contours of a T cell response," *Cancer Letters*, vol. 408, pp. 190–196, 2017.
- [48] M. Martin, A. Guffroy, X. Argemi, and T. Martin, "Systemic lupus erythematosus and lymphopenia: clinical and pathophysiological features," *La Revue de Médecine Interne*, vol. 38, no. 9, pp. 603–613, 2017.
- [49] J. Merayo-Chalico, D. Gómez-Martín, A. Piñeirúa-Menéndez, K. Santana-De Anda, and J. Alcocer-Varela, "Lymphopenia as risk factor for development of severe infections in patients with systemic lupus erythematosus: a case-control study," *QJM: An International Journal of Medicine*, vol. 106, no. 5, pp. 451–457, 2013.
- [50] W. L. Ng, C. M. Chu, A. K. Wu, V. C. Cheng, and K. Y. Yuen, "Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus," *QJM*, vol. 99, no. 1, pp. 37–47, 2006.
- [51] S. J. Rivero, E. Díaz-Jouanen, and D. Alarcón-Segovia, "Lymphopenia in systemic lupus erythematosus," *Arthritis & Rheumatism*, vol. 21, no. 3, pp. 295–305, 1978.



- [52] V. Dhir, A. P. Singh, A. Aggarwal, S. Naik, and R. Misra, "Increased T-lymphocyte apoptosis in lupus correlates with disease activity and may be responsible for reduced T-cell frequency: a cross-sectional and longitudinal study," *Lupus*, vol. 18, no. 9, pp. 785–791, 2009.
- [53] W. Emlen, J. Niebur, and R. Kadera, "Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus," *The Journal of Immunology*, vol. 152, no. 7, pp. 3685–3692, 1994.
- [54] D. Shah, A. Aggarwal, A. Bhatnagar, R. Kiran, and A. Wanchu, "Association between T lymphocyte sub-sets apoptosis and peripheral blood mononuclear cells oxidative stress in systemic lupus erythematosus," *Free Radical Research*, vol. 45, no. 5, pp. 559–567, 2011.
- [55] S. Bashir, G. Harris, M. A. Denman, D. R. Blake, and P. G. Winyard, "Oxidative DNA damage and cellular sensitivity to oxidative stress in human autoimmune diseases," *Annals of the Rheumatic Diseases*, vol. 52, no. 9, pp. 659–666, 1993.
- [56] V. C. Jordan, "The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer," *Endocrine-Related Cancer*, vol. 22, no. 1, pp. R1–R31, 2015.
- [57] D. Khan and S. A. Ahmed, "The immune system is a natural target for estrogen action: opposing effects of estrogen in two prototypical autoimmune diseases," *Frontiers in Immunology*, vol. 6, 2016.
- [58] S. Kovats, "Estrogen receptors regulate innate immune cells and signaling pathways," *Cellular Immunology*, vol. 294, no. 2, pp. 63–69, 2015.
- [59] J. A. Mobley and R. W. Brueggemeier, "Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer," *Carcinogenesis*, vol. 25, no. 1, pp. 3–9, 2004.
- [60] B. T. Zhu and A. J. Lee, "NADPH-dependent metabolism of  $17\beta$ -estradiol and estrone to polar and nonpolar metabolites by human tissues and cytochrome P450 isoforms," *Steroids*, vol. 70, no. 4, pp. 225–244, 2005.
- [61] N. Couto, J. Wood, and J. Barber, "The role of glutathione reductase and related enzymes on cellular redox homeostasis network," *Free Radical Biology and Medicine*, vol. 95, pp. 27–42, 2016.
- [62] I. Jochmanová, Z. Lazúrová, M. Rudnay, I. Bačová, M. Mareková, and I. Lazúrová, "Environmental estrogen bisphenol A and autoimmunity," *Lupus*, vol. 24, no. 4-5, pp. 392–399, 2015.
- [63] M. Adeel, X. Song, Y. Wang, D. Francis, and Y. Yang, "Environmental impact of estrogens on human, animal and plant life: a critical review," *Environment International*, vol. 99, pp. 107–119, 2017.
- [64] A. Ben-Chetrit and E. Ben-Chetrit, "Systemic lupus erythematosus induced by ovulation induction treatment," *Arthritis & Rheumatism*, vol. 37, no. 11, pp. 1614–1617, 1994.
- [65] K. Sharif, A. Watad, L. Coplan et al., "The role of stress in the mosaic of autoimmunity: an overlooked association," *Autoimmunity Reviews*, vol. 17, no. 10, pp. 967–983, 2018.
- [66] E. F. Morand, "Systemic lupus erythematosus: stress and the onset of SLE," *Nature Reviews Rheumatology*, vol. 14, no. 3, pp. 127–128, 2018.
- [67] D. S. Goldstein, "Adrenal responses to stress," *Cellular and Molecular Neurobiology*, vol. 30, no. 8, pp. 1433–1440, 2010.
- [68] S. B. Pruetz, "Stress and the immune system," *Pathophysiology*, vol. 9, no. 3, pp. 133–153, 2003.
- [69] S. C. Segerstrom and G. E. Miller, "Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry," *Psychological Bulletin*, vol. 130, no. 4, pp. 601–630, 2004.
- [70] K. Viswanathan and F. S. Dhabhar, "Stress-induced enhancement of leukocyte trafficking into sites of surgery or immune activation," *Proceedings of the National Academy of Sciences*, vol. 102, no. 16, pp. 5808–5813, 2005.
- [71] V. M. Sanders, "The beta2-adrenergic receptor on T and B lymphocytes: do we understand it yet?," *Brain, Behavior, and Immunity*, vol. 26, no. 2, pp. 195–200, 2012.
- [72] X. Fan and Y. Wang, " $\beta$ 2 adrenergic receptor on T lymphocytes and its clinical implications," *Progress in Natural Science*, vol. 19, no. 1, pp. 17–23, 2009.
- [73] A. J. Case, C. T. Roessner, J. Tian, and M. C. Zimmerman, "Mitochondrial superoxide signaling contributes to norepinephrine-mediated T-lymphocyte cytokine profiles," *PLoS one*, vol. 11, no. 10, p. e0164609, 2016.
- [74] V. J. Thannickal and B. L. Fanburg, "Reactive oxygen species in cell signaling," *American Journal of Physiology-Lung Cellular and Molecular Physiology*, vol. 279, no. 6, pp. L1005–L1028, 2000.
- [75] P. Gergely Jr., C. Grossman, B. Niland et al., "Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus," *Arthritis and Rheumatism*, vol. 46, no. 1, pp. 175–190, 2002.
- [76] S. Sakami, A. Nakata, T. Yamamura, and N. Kawamura, "Psychological stress increases human T cell apoptosis in vitro," *Neuroimmunomodulation*, vol. 10, no. 4, pp. 224–231, 2002.
- [77] S. Bose-O'Reilly, K. M. McCarty, N. Steckling, and B. Lettmeier, "Mercury exposure and children's health," *Current Problems in Pediatric and Adolescent Health Care*, vol. 40, no. 8, pp. 186–215, 2010.
- [78] C. C. Mok, B. Leung, B. Fong, and C. K. Wong, "THU0300 serum mercury level and disease activity of systemic lupus erythematosus (SLE): a case-control study," *Annals of the Rheumatic Diseases*, vol. 72, Suppl 3, pp. A267.3–A2A267, 2013.
- [79] A. T. Jan, A. Ali, and Q. Haq, "Glutathione as an antioxidant in inorganic mercury induced nephrotoxicity," *Journal of Postgraduate Medicine*, vol. 57, no. 1, pp. 72–77, 2011.
- [80] F. Rubino, "Toxicity of glutathione-binding metals: a review of targets and mechanisms," *Toxics*, vol. 3, no. 1, pp. 20–62, 2015.
- [81] J. L. Franco, T. Posser, P. R. Dunkley et al., "Methylmercury neurotoxicity is associated with inhibition of the antioxidant enzyme glutathione peroxidase," *Free Radical Biology and Medicine*, vol. 47, no. 4, pp. 449–457, 2009.
- [82] E. C. Somers, M. A. Ganser, J. S. Warren et al., "Mercury exposure and antinuclear antibodies among females of reproductive age in the United States: NHANES," *Environmental Health Perspectives*, vol. 123, no. 8, pp. 792–798, 2015.
- [83] C. S. Via, P. Nguyen, F. Niculescu, J. Papadimitriou, D. Hoover, and E. K. Silbergeld, "Low-dose exposure to inorganic mercury accelerates disease and mortality in acquired murine lupus," *Environmental health perspectives*, vol. 111, no. 10, pp. 1273–1277, 2003.
- [84] R. Do Prado, V. M. D'Almeida, E. Guerra-Shinohara, L. C. Galdieri, M. T. Ferreri, and M. O. Hilario, "Increased concentration of plasma homocysteine in children with systemic

- lupus erythematosus," *Clinical and Experimental Rheumatology*, vol. 24, no. 5, pp. 594–598, 2006.
- [85] A. Martínez-Berriotxo, G. Ruiz-Irastorza, M. V. E. Arberas, M. R. Gutiérrez, and C. A. Errasti, "Plasma homocysteine levels in systemic lupus erythematosus," *Medicina Clinica*, vol. 120, no. 18, pp. 681–685, 2003.
- [86] D. E. Handy, Y. Zhang, and J. Loscalzo, "Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation," *Journal of Biological Chemistry*, vol. 280, no. 16, pp. 15518–15525, 2005.
- [87] D. Bonciani, E. Antiga, V. Bonciolini et al., "Homocysteine serum levels are increased and correlate with disease severity in patients with lupus erythematosus," *Clinical and Experimental Rheumatology*, vol. 34, no. 1, pp. 76–81, 2016.
- [88] S.-k. Yang, H.-r. Zhang, S.-p. Shi et al., "The role of mitochondria in systemic lupus erythematosus: a glimpse of various pathogenetic mechanisms," *Current Medicinal Chemistry*, vol. 26, 2018.
- [89] H. T. Lee, T. H. Wu, C. S. Lin et al., "The pathogenesis of systemic lupus erythematosus - from the viewpoint of oxidative stress and mitochondrial dysfunction," *Mitochondrion*, vol. 30, pp. 1–7, 2016.
- [90] H. T. Lee, C. S. Lin, W. S. Chen, H. T. Liao, C. Y. Tsai, and Y. H. Wei, "Leukocyte mitochondrial DNA alteration in systemic lupus erythematosus and its relevance to the susceptibility to lupus nephritis," *International Journal of Molecular Sciences*, vol. 13, no. 7, pp. 8853–8868, 2012.
- [91] S. DiMauro and E. A. Schon, "Mitochondrial respiratory-chain diseases," *The New England Journal of Medicine*, vol. 348, no. 26, pp. 2656–2668, 2003.
- [92] K. J. Krishnan, L. C. Greaves, A. K. Reeve, and D. Turnbull, "The ageing mitochondrial genome," *Nucleic Acids Research*, vol. 35, no. 22, pp. 7399–7405, 2007.
- [93] J. H. Santos, J. N. Meyer, and B. Van Houten, "Mitochondrial localization of telomerase as a determinant for hydrogen peroxide-induced mitochondrial DNA damage and apoptosis," *Human Molecular Genetics*, vol. 15, no. 11, pp. 1757–1768, 2006.
- [94] A. Dlasková, L. Hlavatá, and P. Ježek, "Oxidative stress caused by blocking of mitochondrial complex I H<sup>+</sup> pumping as a link in aging/disease vicious cycle," *The International Journal of Biochemistry & Cell Biology*, vol. 40, no. 9, pp. 1792–1805, 2008.
- [95] D. C. Wallace, "Mitochondrial diseases in man and mouse," *Science*, vol. 283, no. 5407, pp. 1482–1488, 1999.
- [96] R. W. Taylor and D. M. Turnbull, "Mitochondrial DNA mutations in human disease," *Nature Reviews. Genetics*, vol. 6, no. 5, pp. 389–402, 2005.
- [97] C. Ricci, V. Pastukh, J. Leonard et al., "Mitochondrial DNA damage triggers mitochondrial-superoxide generation and apoptosis," *American Journal of Physiology. Cell Physiology*, vol. 294, no. 2, pp. C413–C422, 2008.
- [98] J. A. Canter, A. Eshaghian, J. Fessel et al., "Degree of heteroplasmy reflects oxidant damage in a large family with the mitochondrial DNA A8344G mutation," *Free Radical Biology & Medicine*, vol. 38, no. 5, pp. 678–683, 2005.
- [99] L. C. Greaves and R. W. Taylor, "Mitochondrial DNA mutations in human disease," *IUBMB Life*, vol. 58, no. 3, pp. 143–151, 2006.
- [100] Y. Wang, J. Fang, C. Li et al., "Oxidative damage to mtDNA increases ROS," *Mitochondrion*, vol. 6, no. 5, 2006.
- [101] A. M. Jorge and T. K. Means, "Abnormalities in immune complex clearance and apoptotic cell clearance," in *Dubois' Lupus Erythematosus and Related Syndromes*, D. Wallace and B. Hannahs Hahn, Eds., pp. 216–223, Elsevier Inc., 2019.
- [102] S. Caruso and I. K. H. Poon, "Apoptotic cell-derived extracellular vesicles: more than just debris," *Frontiers in Immunology*, vol. 9, 2018.
- [103] S. Arandjelovic and K. S. Ravichandran, "Phagocytosis of apoptotic cells in homeostasis," *Nature Immunology*, vol. 16, no. 9, pp. 907–917, 2015.
- [104] K. W. Yoon, "Dead cell phagocytosis and innate immune checkpoint," *BMB Reports*, vol. 50, no. 10, pp. 496–503, 2017.
- [105] M. Herrmann, R. E. Voll, O. M. Zoller, M. Hagenhofer, B. B. Ponner, and J. R. Kalden, "Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus," *Arthritis and Rheumatism*, vol. 41, no. 7, pp. 1241–1250, 1998.
- [106] C. J. Martin, K. N. Peters, and S. M. Behar, "Macrophages clean up: efferocytosis and microbial control," *Current Opinion in Microbiology*, vol. 17, pp. 17–23, 2014.
- [107] P. G. Chandak, B. Radović, E. Aflaki et al., "Efficient phagocytosis requires triacylglycerol hydrolysis by adipose triglyceride lipase," *Journal of Biological Chemistry*, vol. 285, no. 26, pp. 20192–20201, 2010.
- [108] A. P. West, I. E. Brodsky, C. Rahner et al., "TLR signalling augments macrophage bactericidal activity through mitochondrial ROS," *Nature*, vol. 472, no. 7344, pp. 476–480, 2011.
- [109] L. E. Sander and J. Garaude, "The mitochondrial respiratory chain: a metabolic rheostat of innate immune cell-mediated antibacterial responses," *Mitochondrion*, vol. 41, pp. 28–36, 2018.
- [110] K. J. Li, C. H. Wu, S. C. Hsieh, M. C. Lu, C. Y. Tsai, and C. L. Yu, "Deranged bioenergetics and defective redox capacity in T lymphocytes and neutrophils are related to cellular dysfunction and increased oxidative stress in patients with active systemic lupus erythematosus," *Clinical and Developmental Immunology*, vol. 2012, Article ID 548516, 2012.
- [111] D. Shah, N. Mahajan, S. Sah, S. K. Nath, and B. Paudyal, "Oxidative stress and its biomarkers in systemic lupus erythematosus," *Journal of Biomedical Science*, vol. 21, no. 1, 2014.
- [112] H. A. Papadaki, D. T. Boumpas, F. M. Gibson et al., "Increased apoptosis of bone marrow CD34+ cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus," *British Journal of Haematology*, vol. 115, no. 1, pp. 167–174, 2001.
- [113] A. L. Hepburn, I. A. Lampert, J. J. Boyle et al., "In vivo evidence for apoptosis in the bone marrow in systemic lupus erythematosus," *Annals of the Rheumatic Diseases*, vol. 66, no. 8, pp. 1106–1109, 2007.
- [114] J. W. Park, S. Y. Moon, J. H. Lee et al., "Bone marrow analysis of immune cells and apoptosis in patients with systemic lupus erythematosus," *Lupus*, vol. 23, no. 10, pp. 975–985, 2014.
- [115] S. Rajagopalan, E. C. Somers, R. D. Brook et al., "Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity," *Blood*, vol. 103, no. 10, pp. 3677–3683, 2004.
- [116] B. Baima and M. Sticherling, "Apoptosis in different cutaneous manifestations of lupus erythematosus," *British Journal of Dermatology*, vol. 144, no. 5, pp. 958–966, 2001.

- [117] H. Makino, H. Sugiyama, Y. Yamasaki, Y. Maeshima, J. Wada, and N. Kashihara, "Glomerular cell apoptosis in human lupus nephritis," *Virchows Archiv*, vol. 443, no. 1, pp. 67–77, 2003.
- [118] A. Midgley, Z. McLaren, R. J. Moots, S. W. Edwards, and M. W. Beresford, "The role of neutrophil apoptosis in juvenile-onset systemic lupus erythematosus," *Arthritis & Rheumatism*, vol. 60, no. 8, pp. 2390–2401, 2009.
- [119] M. J. Kaplan, "Apoptosis in systemic lupus erythematosus," *Clinical Immunology*, vol. 112, no. 3, pp. 210–218, 2004.
- [120] X. Li, L. Liu, D. Meng et al., "Enhanced apoptosis and senescence of bone-marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus," *Stem Cells and Development*, vol. 21, no. 13, pp. 2387–2394, 2012.
- [121] C. G. Katsiari, S. N. Liossis, and P. P. Sfikakis, "The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: a reappraisal," *Seminars in Arthritis and Rheumatism*, vol. 39, no. 6, pp. 491–503, 2010.
- [122] Y. Sherer, A. Gorstein, M. J. Fritzler, and Y. Shoenfeld, "Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients," *Seminars in Arthritis and Rheumatism*, vol. 34, no. 2, pp. 501–537, 2004.
- [123] M. R. Arbuckle, M. T. McClain, M. V. Rubertone et al., "Development of autoantibodies before the clinical onset of systemic lupus erythematosus," *New England Journal of Medicine*, vol. 349, no. 16, pp. 1526–1533, 2003.
- [124] A. A. Bengtsson, G. Sturfelt, B. Gullstrand, and L. Truedsson, "Induction of apoptosis in monocytes and lymphocytes by serum from patients with systemic lupus erythematosus – an additional mechanism to increased autoantigen load?," *Clinical and Experimental Immunology*, vol. 135, no. 3, pp. 535–543, 2004.
- [125] A. A. Bengtsson, B. Gullstrand, L. Truedsson, and G. Sturfelt, "SLE serum induces classical caspase-dependent apoptosis independent of death receptors," *Clinical Immunology*, vol. 126, no. 1, pp. 57–66, 2008.
- [126] Y. Ren, J. Tang, M. Y. Mok, A. W. Chan, A. Wu, and C. S. Lau, "Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus," *Arthritis and Rheumatism*, vol. 48, no. 10, pp. 2888–2897, 2003.
- [127] G. Gutiérrez-Venegas, A. Guadarrama-Solís, C. Muñoz-Seca, and J. A. Arreguín-Cano, "Hydrogen peroxide-induced apoptosis in human gingival fibroblasts," *International journal of clinical and experimental pathology*, vol. 8, no. 12, pp. 15563–15572, 2015.
- [128] T. Ishii and G. E. Mann, "Redox status in mammalian cells and stem cells during culture in vitro: critical roles of Nrf2 and cystine transporter activity in the maintenance of redox balance," *Redox Biology*, vol. 2, pp. 786–794, 2014.
- [129] P. J. Vernon and D. Tang, "Eat-me: autophagy, phagocytosis, and reactive oxygen species signaling," *Antioxidants & Redox Signaling*, vol. 18, no. 6, pp. 677–691, 2013.
- [130] A. D. Wentworth, L. H. Jones, P. Wentworth, K. D. Janda, and R. A. Lerner, "Antibodies have the intrinsic capacity to destroy antigens," *Proceedings of the National Academy of Sciences*, vol. 97, no. 20, pp. 10930–10935, 2000.
- [131] M. B. Urowitz, M. Feletar, I. N. Bruce, D. Ibañez, and D. D. Gladman, "Prolonged remission in systemic lupus erythematosus," *The Journal of Rheumatology*, vol. 32, no. 8, pp. 1467–1472, 2005.
- [132] M. Zen, L. Iaccarino, M. Gatto et al., "Prolonged remission in Caucasian patients with SLE: prevalence and outcomes," *Annals of the Rheumatic Diseases*, vol. 74, no. 12, pp. 2117–2122, 2015.
- [133] Z. W. Lai, R. Hanczko, E. Bonilla et al., "N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double-blind, placebo-controlled trial," *Arthritis and Rheumatism*, vol. 64, no. 9, pp. 2937–2946, 2012.
- [134] R. J. Garcia, L. Francis, M. Dawood, Z. W. Lai, S. V. Faraone, and A. Perl, "Brief report: attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus," *Arthritis and Rheumatism*, vol. 65, no. 5, pp. 1313–1318, 2013.